Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963281 · ClinicalTrials.gov registry record · Phase 1
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 285
- Enrollment target
- 9
- Study locations
NCT06963281: Recruiting Phase 1 study of Solid Tumors, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co..
NCT06963281 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Innovent Biopharmaceutical Technology (Hangzhou) Co.. The registered enrollment target is 285 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06963281, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 285 participants
- Enrollment target
- 9
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Primary Outcome
defined as any untoward medical occurrence, whether or not there is a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
Conditions Studied
Interventions
- DRUG IBI3020
Study Locations (9)
Texas
- NEXT Houston - Houston
- NEXT Dallas - Irving
Arizona
- Mayo Clinic - Arizona - Pheonix
Florida
- Mayo Clinic - Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Montefiore Cancer Center - New York
Guangdong
- The sixth affiliated hospital, Sun Yat-sen University - Guangzhou
Shandong
- Shandong Cancer Hospital - Jinan
Shanxi
- Shanxi Cancer Hospital - Taiyuan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
What NCT06963281 shows while recruiting
NCT06963281 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IBI3020 is the first listed.
NCT06963281 lists 9 locations in 8 states (Texas, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT06963281 about?
NCT06963281 is a clinical study titled "Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors". The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
What is the current status of trial NCT06963281?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 285 participants. The study started on 2025-04-29. Estimated completion is 2028-03-31.
What conditions does trial NCT06963281 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06963281?
The interventions under investigation include: IBI3020 (DRUG).
Who is sponsoring clinical trial NCT06963281?
This trial is sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963281 being conducted?
This trial has 9 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06963281's enrollment target sits among peer trials
285 18th of 125 higher than 108 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI